Partner Mark Faccenda spoke with Modern Healthcare to discuss the 340B drug discount program and how decisions made by Congress will impact it.

Mark represents health care industry clients on regulatory and transactional matters. His clients include health systems, physician groups and ancillary healthcare providers as well as drug, device, food and cosmetic manufacturers.

View the full Modern Healthcare article, “340B is back on deck in Congress after Chevron, but hurdles loom.”

Contact